David Rolfe (Trades, Portfolio) recently submitted the 13F filing for the second quarter of 2025, providing insights int ...

From supporting identification of certain cell characteristics to complementing clinical expertise with remote pathologist ...

Zoetis’ second quarter saw revenue and adjusted earnings surpass Wall Street expectations, but the market responded ...

The reality is that people and animals will always need medicine, treatments, and other products to live long and comfortable ...

Zoetis Inc. (NYSE:ZTS) today announced that it has agreed to sell $1.850 billion of senior notes, consisting of $850.0 million aggregate principal amount of 4.150% senior notes due 2028 and $1.0 ...

Worse still, if you'd only held Zoetis stock for the past one, or three, or five years, you would have lost money. Zoetis ...

Hypnotic Video of GIGANTIC US Aircraft Carriers in the Middle of the Sea 'Alligator Alcatraz' migrant detention camp in ...

Animal health firm Zoetis Inc. (NYSE:ZTS) on Tuesday reported a second-quarter 2025 adjusted earnings per share of $1.76, up ...

Zoetis Inc. Q2 2025 earnings highlight 8% organic revenue growth, raised guidance, and strong performance from Simparica and Key Dermatology franchises.

Zoetis (ZTS) stock surges premarket as the company posts strong Q2 2025 results and raises full-year outlook. Read more here.